Drug Trial Radar · NCT05274659
A Study to Evaluate the Safety and Tolerability of KJ103 in Healthy Adults
Last checked: Nov 19, 2026Latest source record: Aug 13, 2024 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
34
Actual
Start
May 19, 2022
Primary completion
Mar 18, 2023
Study completion Aug 18, 2023
Sponsor
- Lead sponsor
- Shanghai Bao Pharmaceuticals Co., Ltd.Industry
- Sponsor type
- Industry
- First posted
- Mar 10, 2022
Design
- Study type
- Interventional
- Phase
- Phase 1
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Single (participant)
- Primary purpose
- Treatment
- FDA-regulated drug
- No
- Who can join
- All sexes, from 18 years, up to 55 years
- Healthy volunteers
- Yes
Summary
As written by the sponsor on the registry.
This is a randomized, single-blinded, placebo controlled, single ascending dose phase I study to evaluate the safety, tolerability, pharmacokinetics (PK) and pharmacodynamics (PD) and immunogenicity of KJ103 in healthy subjects.
Conditions
- Healthy
Interventions
KJ103Drug
Recombinant Immunoglobulin G Cleaving Enzyme
PlaceboDrug
Placebo
Primary outcomes
What the sponsor says the trial is designed to measure.
- AETime frame: Day 1 through Day 14
Locations
1 site in 1 country. Site status is shown where the registry gives one.
New Zealand Clinical Research
Auckland, New Zealand
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.